MetaCap

Evolus Inc. (EOLS)

NASDAQ: EOLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.52-0.48 (-6.86%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EOLS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$431.55M
EPS (TTM)
-$0.48
52-week range
3.86 – 9.31
Day range
6.50 – 7.19
Volume / Avg
813.65K / 925.77K
Beta
—

52-week range

$3.86$9.31

EOLS stock today

On Nov 20, EOLS ended the session at $6.52, shedding $0.48 (6.86%), versus the S&P 500's 3.70% decline. Shares are 30.0% below their 52-week high of $9.31, set on Sep 4, 2026 and 68.9% above the 52-week low of $3.86, in the middle of the past year's range. EOLS is down 2.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.8%.

Evolus has posted a net loss over the last twelve months (EPS of -$0.48), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Evolus

Company profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. David Moatazedi
Headquarters
Newport Beach, CA
Employees
365
IPO year
2018
Website
evolus.com

Financial highlights

Full financials

In fiscal 2025, Evolus generated $297.2 million in revenue, up 11.6% from fiscal 2024, its 7th consecutive year of revenue growth. Evolus reported a net loss of $51.6 million, compared with a loss of $50.4 million a year earlier. Gross margin was 66.3% (down from 68.5%) and operating margin -11.0%.

Evolus annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$297.18M$266.27M$202.09M$148.62M$99.67M
Growth+11.61%+31.76%+35.98%+49.10%+76.29%
Net income$-51.64M$-50.42M$-61.69M$-74.41M$-46.81M
EPS (diluted)$-0.80$-0.81$-1.08$-1.33$-0.94

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$15.40+136.20%

  • Strong buy 1
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.19 vs $-0.14
Surprise
-35.71%

EOLS news

All EOLS news

Evolus peers

Health Care sector
EOLS peer companies
CompanyPrice% ChgMarket capCompare
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs EOLS
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs EOLS
ARVNArvinas Inc.6.46-4.15%$423.03Mvs EOLS
PRTAProthena Corporation plc8.22-2.14%$422.10Mvs EOLS
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs EOLS
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs EOLS
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs EOLS
CRMDCorMedix Inc.5.27+3.74%$419.16Mvs EOLS

Indexes, lists and sector

Evolus stock FAQ

What is Evolus's stock price today?

EOLS last traded at $6.52 as of Nov 20, 4:00 PM EST, down 6.86% on the day. Prices are delayed at least 15 minutes.

Who is Evolus's CEO?

Mr. David Moatazedi is the chief executive officer of Evolus Inc., which has about 365 employees.

What is the EOLS 52-week high?

The 52-week high for EOLS is $9.31 and the 52-week low is $3.86. The stock is currently 30.0% below its high.

Compare EOLS